Basic information Safety Supplier Related
ChemicalBook >  Product Catalog >  API >  Hormones and the Endocrine System >  Lanreotide

Lanreotide

Basic information Safety Supplier Related

Lanreotide Basic information

Product Name:
Lanreotide
Synonyms:
  • LANREOTIDE
  • AUTOGEL
  • BETA-(2-NAPHTHYL)-D-ALA-CYS-TYR-D-TRP-LYS-VAL-CYS-THR AMIDE
  • BIM-23014
  • ANGIOPEPTIN
  • H-D-2-NAL-CYS-TYR-D-TRP-LYS-VAL-CYS-THR-NH2
  • H-D-2-NAL-CYS-TYR-D-TRP-LYS-VAL-CYS-THR-NH2, (DISULFIDE BOND)
  • IPSTYL
CAS:
108736-35-2
MF:
C54H69N11O10S2
MW:
1096.32
EINECS:
689-178-4
Product Categories:
  • hormones
Mol File:
108736-35-2.mol
More
Less

Lanreotide Chemical Properties

Boiling point:
1508.2±65.0 °C(Predicted)
Density 
1.40±0.1 g/cm3(Predicted)
storage temp. 
Keep in dark place,Sealed in dry,Store in freezer, under -20°C
pka
9.90±0.15(Predicted)
Sequence
D-2-Nal-[Cys-Tyr-D-Trp-Lys-Val-Cys]-Thr-NH2
InChIKey
PUDHBTGHUJUUFI-VHAAONQQNA-N
More
Less

Safety Information

WGK Germany 
3
HS Code 
3504009000

MSDS

More
Less

Lanreotide Usage And Synthesis

Description

Lanreotide is a synthetic octapeptide analogue of somatostatin with enhanced metabolic stability compared with somatostatin. It binds with high affinity to and stimulates the somatostatin receptors SSTR2 and SSTR5, with relatively greater potency at SSTR2 and very low binding to SSTR1, SSTR3 and SSTR4. It is used to treat acromegaly and neuroendocrine tumors.

Chemical Properties

White to off-white lyophilised powder

Uses

Antineoplas tic.

Side effects

Lanreotide depot was generally well tolerated, as 88% of patients had adverse events, compared with the placebo at 90%. Most adverse events were mild (17%) or moderate (44%) in both lanreotide and placebo groups. The most common adverse event was diarrhea at 26% in the lanreotide group and 9% with placebo. Abdominal pain was recorded in 14% of patients taking lanreotide but only occurred in 2% of patients taking placebo. Cholelithiasis occurred in 10% of patients but only 3% in the placebo group. Hyperglycemia occurred in 5% of lanreotide patients but was not observed in placebo patients.

LanreotideSupplier

Hangzhou Peptidego Biotech Co.,Ltd. Gold
Tel
0571-87213919
Email
Eric@peptidego.com
Hangzhou Peptide Biochem Co.,Ltd Gold
Tel
0571-89197072; 18668118770
Email
linda@peptide-china.com
Hangzhou nuotong biotechnology co. LTD Gold
Tel
0571-86297909 15268405618
Email
sisi.xiang@sinopep.com
Shaoxing Junyu Biotechnology Co., LTD Gold
Tel
0571-88211921 15572296305
Email
sales4@gotopbio.com
Zhejiang Jiekun Biotechnology Co., Ltd Gold
Tel
0571-88211951 13735575465
Email
sales1@gotopbio.com